2 February 2024
RNS Reach
Physiomics plc
("Physiomics" or "the Company")
IMC Presentation on Company
Website
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, recently provided a brief update on the
Board changes via Investor Meet
Company and has updated its website with the
presentation.
The presentation and
Q&A from the meeting are now available at the
Company's website:
www.physiomics.co.uk/portfolio-item/investor-presentation-board-changes
Enquiries:
Physiomics
plc
Dr Jim Millen, Non-Executive Chairman, +44
(0)1235 841575
Dr Peter Sargent, Chief Executive Officer, +44
(0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.